CNBC
01 Jun 2026, 14:00 UTC · 16w ago
Verdict
Headline takes no side. We score CMPS +1.00 across two claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Compass Pathways, Transcend Therapeutics, and Usona Institute have received priority FDA review vouchers via executive order.
More positive than 99% of claims this week
The Trump administration is pushing to fast-track the approval of psychedelic drugs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 86% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company received a priority FDA review voucher, which significantly accelerates the drug approval process.
More positive than 15% of relationship scores this week
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
More positive than 15% of relationship scores this week
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
More positive than 15% of relationship scores this week
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
+5.3%
Price agrees with the score
$13.75 vs $13.06 close before publication (May 29) · not market-adjusted
CMPS chart →
